Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.
By P. Amarenco, J. Labreuche. Lancet Neurology, 2009
624 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/179fa7563b53eca6df8665a0829e37b5ab182944
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “Major statin trials reported significant reductions in stroke rates in patients with CHD or at high risk due to a reduction in the rates of ischaemic stroke.(469) Increased concentrations of triglycerides and low HDL cholesterol are also associated with non-haemorrhagic stroke.”
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “In a meta-analysis of RCTs enrolling >90 000 patients, statin therapy did lead to a 21% reduction in the incidence of all strokes in different populations; this effect was mainly driven by the extent of LDL-C reduction.(460)”
- Guidelines for the Primary Prevention of Stroke (2011, neutral): “5; P=0·009) reduction in stroke.(155) Several meta-analyses also found that beneficial effects are greater with greater lipid lowering.”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.(422,428) Statin pretreatment at TIA onset was associated with reduced recurrent early stroke risk in patients with carotid stenosis in a pooled data analysis, supporting an as-early-as-pos”
- Stroke Risk Factors, Genetics, and Prevention (2017, background): “Furthermore, meta-analyses of lipid therapy and stroke showed that with each 1 mmol/L reduction in LDL cholesterol, there was an ≈20% relative risk reduction in ischemic stroke.(253,254) The role for statin therapy in stroke prevention is also evident in secondary prevention studies.”
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “More intensive lipid lowering with statins is associated with lower risk of stroke compared with less intensive regimens.(210)”
- Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “reduce LDL-C levels, have proved efficacious in reducing primary stroke risk without any significant risk of ICH.(60) In the only trial to date dedicated to the evaluation of secondary”
- Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, neutral): “08).(149) There is also no evidence of increased risk”